Request Your Free Trend Report Now:

"The Latest Developments in Oncology Research"

Explore what's new in oncology research in our latest Trendline.

Drugmakers and, largely, the FDA argue that the medicines now being reviewed are different than the chemotherapies and blunter interventions of the past. This is having consequences for how clinical trials are being run, and for how much money drugmakers are investing in cancer R&D.

Included in this Trendline:

• AstraZeneca’s $80B sales plan leans on cancer drug expansion
• Why selling to Novartis made sense for a radiopharmaceutical startup
• Pfizer, looking for a jumpstart, leans into cancer drug research

Offered Free by: BioPharma Dive and Bio-Rad
See All Resources from: BioPharma Dive and Bio-Rad